DualityBio Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS10
PHASE 3 / 2-32
RECRUITING7
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO78%
Delay Index: of 9 active trials registered more than a year ago, 7 have moved their primary completion (readout) date by more than 6 months since first registration (median +16.0 months). See all sponsors →
Open DualityBio Inc. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| DB-1303/BNT323 NCT06018337 |
P3 | Active, not recruiting | Metastatic Breast Cancer | 541 | 2026-08-12 (+12 mo) |
| DB-1419 NCT06554795 |
P1/2 | Recruiting | Solid Tumor, Adult | 360 | 2027-02 |
| DB-2304 NCT06625671 |
P1/2 | Recruiting | Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus | 148 | 2027-06-30 (+15 mo) |
| DB-1303/BNT323 NCT05150691 |
P1/2 | Recruiting | HER2-positive Advanced Solid Tumor | 796 | 2027-08 (+26 mo) |
| DB-1305/BNT325 NCT05438329 |
P1/2 | Active, not recruiting | Advanced Solid Tumor | 1123 | 2027-08-13 (+25 mo) |
| DB-1311 NCT05914116 |
P1/2 | Recruiting | Advanced Solid Tumors | 862 | 2027-12 (+32 mo) |
| DB-1303/BNT323 NCT06265428 |
P3 | Active, not recruiting | HER2-positive Breast Cancer | 228 | 2027-12 (+22 mo) |
| DB-1310 NCT05785741 |
P1/2 | Recruiting | Advanced Solid Tumor | 1000 | 2027-12-30 (+16 mo) |
| DB-1324 NCT07263594 |
P1/2 | Recruiting | Gastrointestinal Cancer | 127 | 2028-12 |
| DB-1311/BNT324 NCT06953089 |
P2 | Recruiting | Solid Tumors | 750 | 2030-06-30 |